<PAGE>
                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                    QUARTERLY REPORT FOR THE QUARTERLY PERIOD
                            ENDED SEPTEMBER 30, 2003

                           COMMISSION FILE NO. 0-28077

                                 GENELINK, INC.
                 ----------------------------------------------
                 (Name of Small Business Issuer in its charter)


           PENNSYLVANIA                                  23-2795613
           ------------                                  ----------
    (State or other jurisdiction of         (I.R.S. Employer Identification No.)
    incorporation or organization)


           100 S. Thurlow Street
           Margate, New Jersey                              08402
           -------------------                              -----
(Address of principal executive offices)                 (Zip Code)

                    ISSUER'S TELEPHONE NUMBER: (609) 823-6991


      Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No ___

      APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares
outstanding of each of the issuer's classes of common stock, as of the latest
practicable date.

      Number of Shares of Common Stock
      Outstanding on November 5, 2003             27,716,319
                                                  ----------

      Transitional Small Business Disclosure Format Yes ___ No X


                                       1
<PAGE>
                                 GENELINK, INC.

PART I.     FINANCIAL INFORMATION

ITEM 1.     Financial Statements.

            Balance Sheets at September 30, 2003 (unaudited) and December 31,
            2002

            Statements of Operations for the three months and nine months ended
            September 30, 2003 and 2002 (unaudited)

            Statements of Cash Flows for the nine months ended September 30,
            2003 and 2002 (unaudited)

            Notes to Financial Statements


                                       2
<PAGE>
                                 GENELINK, INC.
                                 BALANCE SHEETS


<TABLE>
<CAPTION>
                                                 (UNAUDITED)
                                                SEPTEMBER 30,      DECEMBER 31,
                                                    2003               2002
                                                -------------      -----------
<S>                                             <C>                <C>
ASSETS
Cash                                             $    77,855       $    31,203
Accounts receivable                                   33,918             2,675
Inventory                                             21,774            26,180
Prepaid expenses                                      73,841            84,866
                                                 -----------       -----------
   Total current assets                              207,388           144,924
Property and equipment                                74,651            70,881
Other assets                                         115,140           103,336
                                                 -----------       -----------
                                                 $   397,179       $   319,141
                                                 ===========       ===========
LIABILITIES
Accounts payable and accrued expenses            $   322,132       $   275,024
Accrued payroll taxes                                 52,990            20,774
Deferred revenue                                      14,985                 0
                                                 -----------       -----------
   Total current liabilities                         340,107           295,798
Accrued compensation                                 314,345           332,531
Loans payable-affiliates                              43,000            53,000
                                                 -----------       -----------
                                                     747,452           681,329
                                                 -----------       -----------
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $.01 par value,
   75,000,000 shares authorized
   27,362,611 and 19,123,130 shares
   issued, 27,166,431 and 18,926,950
   outstanding as of September 30,
   2003 and December 31, 2002, respectively          273,626           191,232
Treasury stock, 196,180 shares
   as of September 30, 2003 and
   December 31, 2002, respectively                  (205,860)         (205,860)
Additional paid-in capital                         6,406,366         6,031,368
Stock subscriptions receivable                    (1,035,619)         (970,146)
Stock warrants                                     1,572,427           779,877
Accumulated deficit                               (7,361,213)       (6,188,659)
                                                 -----------       -----------
                                                    (350,273)         (362,188)
                                                 -----------       -----------
                                                 $   397,179       $   319,141
                                                 ===========       ===========
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       3
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
THREE MONTHS ENDED SEPTEMBER 30,                    2003               2002
                                                ------------       ------------
<S>                                             <C>                <C>
REVENUE                                         $     22,717       $     26,598
COST OF GOODS SOLD                                     8,949              9,388
                                                ------------       ------------
GROSS PROFIT                                          13,768             17,210
                                                ------------       ------------
EXPENSES
   Selling, general and administrative               157,429             95,928
   Consulting                                         43,565             56,350
   Professional fees                                  47,466             43,917
   Advertising and promotion                           7,898             19,767
   Amortization and depreciation                       5,059              2,412
                                                ------------       ------------
                                                     261,417            218,374
                                                ------------       ------------
NET LOSS BEFORE EXTRAORDINARY ITEM                  (247,649)          (201,164)
EXTRAORDINARY ITEM - WRITE-OFF OF ADVANCES
TO RELATED PARTY                                       7,889                  0
                                                ------------       ------------
NET LOSS BEFORE PROVISION FOR INCOME TAXES          (255,538)          (201,164)
PROVISIONS FOR INCOME TAXES                                0                  0
                                                ------------       ------------
NET LOSS                                        $   (255,538)      $   (201,164)
                                                ============       ============
NET LOSS PER SHARE BASIC AND DILUTED            $      (0.01)      $      (0.01)
                                                ============       ============
Weighted average common shares and diluted
potential common shares                           26,288,644         18,233,341
                                                ============       ============
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       4
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)



<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                     2003               2002
                                                ------------       ------------
<S>                                             <C>                <C>
REVENUE                                         $     65,753       $     34,856
COST OF GOODS SOLD                                    36,269             10,622
                                                ------------       ------------
GROSS PROFIT                                          29,484             24,234
                                                ------------       ------------
EXPENSES
   Selling, general and administrative               562,680            573,586
   Consulting                                        153,229            159,872
   Professional fees                                 301,433            109,005
   Advertising and promotion                          33,184             72,910
   Amortization and depreciation                      13,771              6,814
                                                ------------       ------------
                                                   1,064,297            922,187
                                                ------------       ------------
NET LOSS BEFORE EXTRAORDINARY ITEM                (1,034,813)          (897,953)
EXTRAORDINARY ITEM- WRITE-OFF OF ADVANCE
TO RELATED PARTY                                    (137,741)                 0
                                                ------------       ------------
NET LOSS BEFORE PROVISION FOR INCOME TAXES        (1,172,554)          (897,953)
PROVISION FOR INCOME TAXES                                 0                  0
                                                ------------       ------------
NET LOSS                                        $ (1,172,554)      $   (897,953)
                                                ============       ============
NET LOSS PER SHARE BASIC AND DILUTED            $      (0.06)      $      (0.05)
                                                ============       ============
Weighted average common shares and diluted
potential common shares                         $ 21,503,048       $ 17,655,348
                                                ============       ============
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       5
<PAGE>
                                 GENELINK ,INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)



<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                                   2003             2002
                                                              -----------       ---------
<S>                                                           <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss                                                      $(1,172,554)      $(897,953)
Adjustments to reconcile net loss to net cash
  used by operating activities
Depreciation and amortization                                      13,771           6,814
Fair value of compensation related to vested options                    0         200,000
Common stock issued for services                                  828,856         143,860
Common stock issued to related party                               20,000               0
Fair value of options granted for services                         55,700          11,440
Changes in operating assets and liabilities
    Accounts receivable                                           (31,243)        (11,744)
    Inventory                                                       4,406         (18,943)
    Prepaid expenses                                               11,025          11,748
    Accounts payable and accrued expenses                          47,108          63,013
    Accrued payroll taxes                                          32,216          48,559
    Deferred revenue                                               14,985               0

    Accrued compensation                                          (18,186)        (48,856)
                                                              -----------       ---------
Net cash used by operating activities                            (193,916)       (492,062)
                                                              -----------       ---------
CASH FLOWS FROM INVESTING ACTIVITIES
     Advance to officer                                           (31,587)              0
     Capital expenditures                                         (29,345)        (33,291)
     Advance to related party                                           0        (272,021)
                                                              -----------       ---------
Net cash used by investing activities                             (60,932)       (305,312)
                                                              -----------       ---------
CASH FLOWS FROM FINANCING ACTIVITIES
     Reduction of paid in capital                                (448,000)              0
     Proceeds relating to issuance of common stock (net)          759,500         683,000
     Repayment of loans payable                                   (10,000)         (5,000)
                                                              -----------       ---------
     Net cash provided by financing activities                $   301,500       $ 678,000
                                                              -----------       ---------
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       6
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                             2003           2002
                                                          --------      ---------
<S>                                                       <C>           <C>
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS      $ 46,652      $(119,374)

Cash and cash equivalents, beginning of period              31,203        121,434
                                                          --------      ---------
Cash and cash equivalents, end of period                    77,855          2,060
                                                          --------      ---------
SUPPLEMENTARY CASH FLOW INFORMATION
    Income taxes paid                                            0              0
    Interest paid                                                0              0
NON-CASH FINANCING TRANSACTIONS
    Accrued interest on subscriptions receivable            33,886         43,428
    Issuance of common stock for services                  828,856        143,860
    Acquisition of treasury stock                                0         96,000
    Accrued interest on advance to related party            21,024              0
    Issuance of common stock to related party               20,000              0
    Stock option granted for services                       45,500              0
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       7
<PAGE>
                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

1.   DESCRIPTION OF                  BUSINESS ORGANIZATION
     ORGANIZATION                    GeneLink, Inc. (the Company), operating in
                                     New Jersey, was organized under the laws of
                                     the Commonwealth of Pennsylvania. The
                                     Company is the successor to a Delaware
                                     Corporation organized under the same name
                                     on September 21, 1994. The Company's
                                     offices are located in Margate, New Jersey.

                                     BUSINESS DESCRIPTION

                                     The Company was founded in response to the
                                     information being generated in the field of
                                     human molecular genetics. Management
                                     believes future generations could benefit
                                     from the DNA store of knowledge, as
                                     scientists are discovering an increasing
                                     number of connections between genes and
                                     specific diseases. For this reason, the
                                     Company has created a DNA banking service
                                     that stores DNA before and after an
                                     individual dies. This genetic history can
                                     help families determine if they are at risk
                                     for certain inherited diseases. DNA banking
                                     shifts the emphasis from diagnosis and
                                     treatment to detection and prevention.

                                     The Company has developed a patented DNA
                                     Collection Kit for the collection of DNA
                                     specimens of its clients. The DNA will be
                                     stored for 75-year intervals. Upon a
                                     client's request, and upon the payment of a
                                     retrieval fee, the stored DNA specimen can
                                     be retrieved and sent to a laboratory for
                                     testing.

                                     The Company has created proprietary
                                     methodology for SNP (single nucleotide
                                     polymorphism) based on nutragenetic and
                                     dermagenetic profiling. These profiles
                                     (patents pending) provide a means of
                                     predicting an individual's inherent genetic
                                     capacity to combat oxidative stress and
                                     other important selected areas of
                                     physiological health. These profile
                                     assessments enable nutritional and skin
                                     care companies to recommend a specific and
                                     targeted regime of antioxidant vitamins,
                                     nutrients or skin care formulations that
                                     have been specifically designed to
                                     compensate for predicted deficiencies. The
                                     Company's patented DNA Collection Kit will
                                     be used for these assessments.


                                       8
<PAGE>
                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS
--------------------------------------------------------------------------------


2.  BASIS OF                         The accompanying unaudited financial
    PRESENTATION                     statements have been prepared by the
                                     Company in accordance with the instructions
                                     to Form 10-Q and Article 10 of
                                     Regulation S-X relating to interim
                                     financial statements. Accordingly, they do
                                     not include all of the information and
                                     footnotes required by generally accepted
                                     accounting principles for complete
                                     financial statements and should be read in
                                     conjunction with the financial statements
                                     and notes thereto included in the Annual
                                     Report on Form 10-K of GeneLink, Inc. for
                                     the year ended December 31, 2002.

                                     In the opinion of management, all
                                     adjustments (consisting of normal recurring
                                     accruals) necessary to present fairly the
                                     information set forth in the accompanying
                                     financial statements have been included.
                                     The results reported in these financial
                                     statements for the nine-month period ended
                                     September 30, 2003 should not be regarded
                                     as necessarily indicative of results that
                                     may be expected for the year ended December
                                     31, 2003.

3.  SHAREHOLDERS'                    A.  COMMON STOCK
    EQUITY TRANSACTIONS              During the nine months ended September 30,
                                     2003, the Company issued 4,235,000 shares
                                     of common stock and 4,235,000 warrants to
                                     purchase common stock for cash
                                     consideration of $853,000. This is pursuant
                                     to the private placement offerings in 2003
                                     and 2002. Using the Black-Scholes
                                     methodology, the warrants were valued at
                                     $747,050.

                                     The Company issued 558,606 shares of common
                                     stock for services rendered, valued at
                                     $159,681 for the nine months ended
                                     September 30, 2003.

                                     The Company issued options to purchase
                                     130,000 shares of common stock in exchange
                                     for services rendered. The options were
                                     valued at $45,500 using the Black-Scholes
                                     methodology.

                                     The Company issued 60,606 shares of common
                                     stock valued at $20,000 as part of an
                                     advance to a related party.

                                     The Company issued 2,722,345 shares of
                                     common stock to an officer for compensation
                                     due through June 30, 2003 of $544,469. Of
                                     this amount, $448,000 offset additional
                                     paid in capital.

                                     The Company issued 723,530 shares of common
                                     stock valued at $144,706 to the spouse of
                                     an officer for services rendered through
                                     June 30, 2003.


                                       9
<PAGE>
                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS
--------------------------------------------------------------------------------


                                     B.   STOCK OPTIONS AND WARRANTS

                                     During the nine months ended September 30,
                                     2003, $10,200 was charged against
                                     consulting fees for options vested during
                                     the quarter that were issued in prior years
                                     pursuant to consulting agreements.

4.  TRANSACTIONS                     Pursuant to agreements with two officers,
    WITH RELATED PARTIES             compensation of $272,135 was accrued
                                     during the nine months ended September 30,
                                     2003. Of the total accrued compensation,
                                     $193,851 was paid during the nine months
                                     ended September 30, 2003.

                                     The Company advanced an officer $31,587
                                     during the nine months ended September 30,
                                     2003.

                                     The Company issued 2,722,345 shares of
                                     common stock to an officer for compensation
                                     due through June 30, 2003 of $544,469. Of
                                     this amount, $448,000 offset additional
                                     paid in capital.

                                     The Company issued 723,530 shares of common
                                     stock valued at $144,706 to the spouse of
                                     an officer for services rendered through
                                     June 30, 2003.

                                     In connection with a Distribution
                                     Agreement entered into with NuGenix, LLC in
                                     April, 2002 and a related loan for
                                     $500,000, the Company advanced NuGenix
                                     $89,907 in cash, and 60,606 shares of
                                     common stock valued at $20,000 during the
                                     nine months ended September 30, 2003. The
                                     loan is funded in full as of June 30, 2003.
                                     NuGenix is entirely owned by DePhillipo
                                     Family, LLC, which in turn is owned by the
                                     adult children of John R. DePhillipo, the
                                     Chief Executive Officer and President and a
                                     member of the Board of Directors of the
                                     Company.

5.  EXTRAORDINARY                    For the nine months ended September 30,
    ITEM                             2003 the Company had advanced to NuGenix
                                     $109,907 in stock and cash, had interest
                                     receivable of $21,024 and accounts
                                     receivable of $6,810. At the present time,
                                     the Company believes that NuGenix does not
                                     possess the ability to be able to repay the
                                     advances. Therefore, management has
                                     determined that this amount should be
                                     written-off in the current period.


                                       10
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

Statements in this Report that relate to future results and events are based on
the Company's current expectations. Actual results in future periods may differ
materially from those currently expected or desired because of a number of risks
and uncertainties. For a discussion of factors affecting the Company's business
and prospects, see "Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations - Factors Affecting the Company's Business
and Prospects."

Operating results for the nine-month period ended September 30, 2003 are not
necessarily indicative of the results that may be expected for the full fiscal
year.

LIQUIDITY AND CAPITAL RESOURCES

For the nine month period ended September 30, 2003, the Company's primary
liquidity requirements have been research and development, funding of its sales
and marketing efforts, the payment of compensation to officers and other
employees and the payment of accounts payable. In the first nine months of 2003,
the Company has raised $759,500, primarily through the issuance of common stock
and warrants.

Cash and cash equivalents at September 30, 2003 amounted to $77,855 as compared
to $31,203 at December 31, 2002, an increase of $46,652. During the first nine
months of 2003, the Company's operating activities utilized $193,916, as
compared to $492,062 for the first nine months of 2002. Cash utilized during
these periods resulted from Company's net losses for such periods.

Financing activities provided $301,500 for the nine month period ended September
30, 2003 as compared to $678,000 for the nine months ended September 30, 2002.
Financing activities in the nine months ended September 30, 2003 resulted
primarily from the issuance of $759,500 of common stock and warrants throughout
the first nine months of 2003, as offset by a $448,000 reduction to paid in
capital.

The Company will require approximately $1,000,000 for research and development,
for working capital and to pay accounts payable. The Company intends to raise
funds through the private placement of its securities. Unless the Company can
increase its revenues and increase its stock price, it is unlikely that the
Company will be able to secure such financing. If the Company is not able to
secure such additional required capital, it will continue to realize negative
cash flow and losses and may not be able to continue operations.


                                       11
<PAGE>
RESULTS OF OPERATIONS

The following table sets forth certain operating information regarding the
Company:

<TABLE>
<CAPTION>
                                         NINE MONTH PERIOD                        NINE MONTH PERIOD
                                      ENDED SEPTEMBER 30, 2003                ENDED SEPTEMBER 30, 2002
                                      ------------------------                ------------------------

                                            (UNAUDITED)                              (UNAUDITED)
                                            -----------                              -----------
<S>                                   <C>                                     <C>
Revenues                                      $    65,753                            $   34,856

Net earnings (loss) before
extraordinary items                           $(1,034,813)                           $(897,953)

Net earnings (loss) per share                 $     (0.06)                           $   (0.05)
</TABLE>


The following summary table presents comparative cash flows of the Company for
the nine months ended September 30, 2003 and 2002.


<TABLE>
<CAPTION>
                                        NINE MONTH PERIOD                        NINE MONTH PERIOD
                                     ENDED SEPTEMBER 30, 2003                ENDED SEPTEMBER 30, 2002
                                     ------------------------                ------------------------

                                           (UNAUDITED)                              (UNAUDITED)
                                           -----------                              -----------
<S>                                  <C>                                     <C>
Net cash used by
operating activities                         $193,916                                $492,062

Net cash used
by investing activities                      $ 60,932                                $305,312

Net cash provided
by financing activities                      $301,500                                $678,000
</TABLE>


        COMPARISON OF THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2003
             TO THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2002

FINANCIAL CONDITION

Assets of the Company increased from $319,141 at December 31, 2002 to $397,179
at September 30, 2003, an increase of $78,038. This increase was primarily due
to an increase in cash of $31,203 at December 31, 2002 to $77,855 at September
30, 2003, an increase of $46,652, resulting from the Company's sale of
securities, and an increase in accounts receivable from $2,675 at December 31,
2002 to $33,918 at September 30, 2003.

Liabilities increased from $681,329 at December 31, 2002 to $747,452 at
September 30, 2003, an increase of $66,123. This increase in liabilities
primarily resulted from an increase in accounts payable and accrued expenses
from $275,024 at December 31, 2002 to $322,132 at September 30, 2003, an
increase of $47,108.


                                       12
<PAGE>
CURRENT YEAR PERFORMANCE AND EARNINGS OUTLOOK

Revenues. The total revenues for the nine months ended September 30, 2003 were
$65,753 as compared to $34,856 for the nine months ended September 30, 2002, an
increase of $30,897, or 88.6%.

Total revenues for the three months ended September 30, 2003 were $22,717 as
compared to $26,598 for the three months ended September 30, 2002, a decrease of
$3,881, or 14.6%.

Expenses. Total expenses for the nine months ended September 30, 2003 were
$1,064,297 as compared to $922,187 for the nine months ended September 30, 2002,
an increase of $142,110, primarily resulting from an increase in professional
fees from $109,005 for the nine months ended September 30, 2002 to $301,435 for
the nine months ended September 30, 2003, which resulted from the Company's
legal fees associated with the litigation matter described in Part II of this
Quarterly Report.

Total expenses for the three months ended September 30, 2003 were $261,417 as
compared to $218,374 for the three months ended September 30, 2002, an increase
of $43,043, primarily resulting from an increase in selling, general and
administrative expenses from $95,928 for the three months ended September 30,
2002 to $157,429 for the three months ended September 30, 2003, resulting from
increased sales efforts.

Losses. The Company incurred a loss before extraordinary items of $1,034,813 for
the nine months ended September 30, 2003 as compared to a loss of $897,953 for
the nine months ended September 30, 2002, an increase of $136,860, or 15.2%,
primarily resulting from the increase in expenses for the nine months ended
September 30, 2003 of $142,110, as compared to nine months ended September 30,
2002.

The Company incurred a loss of $247,649 for the three months ended September 30,
2003, as compared to a loss of $201,164 for the three months ended September 30,
2002, an increase of $46,485, or 23.1%, primarily resulting from an increase in
expenses the three months ended September 30, 2003 of $43,043, as compared to
the three months ended September 30, 2002.

FACTORS AFFECTING THE COMPANY'S BUSINESS AND PROSPECTS

There are a number of factors that affect the Company's business and the results
of its operations. These factors include general economic and business
conditions; the level of acceptance of the Company's products and services; the
rate and commercial applicability of advancements and discoveries in the
genetics field; the Company's ability to enter into strategic alliances with
companies in the nutragenetics and dermagenetics industries; and the ability of
the Company to raise the financing necessary to implement its business and
marketing plan, to pay salaries to its officers and employees and to pay its
accounts payable.


                                       13
<PAGE>
ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in its Exchange Act reports is
recorded, processed, summarized and reported within the time periods specified
in the Securities and Exchange Commission's rules and forms, and that such
information is accumulated and communicated to management, including the Chief
Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure. Management necessarily applies its
judgment in assessing the costs and benefits of such controls and procedures,
which, by their nature, can provide only reasonable assurance regarding
management's control objectives.

With the participation of management, the Company's Chief Executive Officer and
Chief Financial Officer evaluated the effectiveness of the design and operation
of the Company's disclosure controls and procedures at the conclusion of the
three months ended September 30, 2003. Based upon this evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that the Company's
disclosure controls and procedures were effective in ensuring that material
information required to be disclosed is included in the reports that it files
with the Securities and Exchange Commission.

CHANGES IN INTERNAL CONTROLS

There were no significant changes in the Company's internal controls or, to the
knowledge of management of the Company, in other factors that could
significantly affect internal controls subsequent to the date of the Company's
most recent evaluation of its disclosure controls and procedures utilized to
compile information included in this filing.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

GeneLink v. LAB21, Inc. Civil Action No. 03cv1038 (D.NJ 2003). On March 24,
2003, the United States District Court for the District of New Jersey granted a
preliminary injunction against LAB21, Inc. and its affiliates and
representatives from claiming that LAB21, Inc. developed the use of DNA to
measure and access skincare and skin health or from using any of our
confidential or proprietary information which we disclosed to LAB21, Inc. in
connection with LAB21, Inc.'s testing of our technology.

The Court enjoined and restrained LAB21, Inc. and its officers, employees,
representatives and agents from representing that LAB21, Inc. or anyone
associated with LAB21, Inc. developed, invented or are leaders in the
application of DNA technologies to skincare or skin health or from suggesting
that LAB21, Inc. or any representative or affiliate developed the first skin DNA
test for at home use. The Court further enjoined and restrained LAB21, Inc., its
officers, employees, representatives and agents from utilizing any of our
confidential information shared with LAB21, Inc., its agents and employees, from
utilizing any of our proprietary information concerning measuring and assessing
any genes involved in nutritional, healthcare and skin healthcare evaluations,
or from using any SNP technology in any of LAB21, Inc.'s products. It is
anticipated


                                       14
<PAGE>
that this matter will go to trial prior to the end of 2003.

ITEM 6. Exhibits and Reports on Form 8-K.

        (a) Exhibit No.

            31.1 Certification of Chief Executive Officer and Chief Financial
            Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

            32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted
            pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

        (b) Reports on Form 8-K.

            No reports on Form 8-K were filed during the quarter for which this
            report is filed.

                                   * * * * * *

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                 GENELINK, INC.
                                 --------------
                                  (Registrant)

Date: November 13, 2003              By:         /s/ John R. DePhillipo
                                         ---------------------------------------
                                         John R. DePhillipo, Chief Executive
                                         Officer and Chief Financial Officer


                                       15